Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma.
Irit Avivi,Irit Avivi,Roi Balaban,Tamir Shragai,Tamir Shragai,Gabi Sheffer,Miguel Morales,Anat Aharon,Noa Lowenton-Spier,Svetlana Trestman,Chava Perry,Chava Perry,Noam Benyamini,Noam Benyamini,Moshe Mittelman,Moshe Mittelman,Yaara Tabib,Yaara Tabib,Tali Bar Lev,Tali Bar Lev,Mor Zavaro,Mor Zavaro,Yair Herishanu,Yair Herishanu,Efrat Luttwak,Efrat Luttwak,Yael C Cohen,Yael C Cohen +27 more
TLDR
In conclusion, BNT162b2 vaccine was safe and provided a high seropositivity rate in MM patients, independent of treatment type, and older, hypogammaglobulinaemic and heavily pretreated patients had lower response rates.Abstract:
Multiple myeloma (MM) patients are at excess risk for clinically significant COVID19 infection. BNT162b2 mRNA COVID19 (BNT162b2) vaccine provides effective protection against COVID19 for the general population, yet its effect in MM patients may be compromised due to disease and therapy-related factors and was not yet evaluated. This single-centre prospective study included MM patients tested for serological response 14-21 days post second vaccine. Vaccinated healthy volunteers served as controls. In all, 171 MM patients, median age 70 (38-94) were included; 159 active MM and 12 smouldering myeloma (SMM). Seropositive response rate (median titer) was 76% (91 U/ml) in active MM patients vs 98% (992 U/ml) in the 64 controls (P < 0·0001), and 100% (822 U/ml) in SMM patients. Multivariate analysis revealed older age (P = 0·009), exposure to ≥4 novel anti-myeloma drugs (P = 0·02) and hypogammaglobulinaemia (P = 0·002) were associated with lower response rates. None of the novel agents significantly decreased response rate, whereas daratumumab trended towards reduced response (P = 0·08). Adverse events occurred in 53% and 55% of the MM patients and controls, respectively, all transient grade 1-2. In conclusion, BNT162b2 vaccine was safe and provided a high seropositivity rate in MM patients, independent of treatment type. Older, hypogammaglobulinaemic and heavily pretreated patients had lower response rates.read more
Citations
More filters
Journal ArticleDOI
Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review
Simon Galmiche,Liem Binh Luong Nguyen,Eric Tartour,Xavier de Lamballerie,Linda Wittkop,Paul Loubet,Odile Launay +6 more
TL;DR: In this paper, the authors conducted a systematic review of literature to assess immunogenicity, efficacy and effectiveness of COVID-19 vaccines in immunocompromised populations, including solid organ transplant recipients and patients with haematological malignancy.
Journal ArticleDOI
Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review
TL;DR: In this article , the authors conducted a systematic review of literature to assess immunogenicity, efficacy and effectiveness of COVID-19 vaccines in immunocompromised populations, including solid organ transplant recipients and patients with haematological malignancy.
Journal ArticleDOI
Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting
TL;DR: In this paper , the authors evaluated the relative effectiveness of the mRNA BNT162b2 vaccine in patients with hematological neoplasms compared with matched controls, and found that vaccinated patients had an increased risk of documented COVID-19 infection by polymerase chain reaction; symptomatic infection; hospitalizations; severe COVID19 disease; and COVID -19-related death.
Journal ArticleDOI
Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer: Real-World Evidence From the National COVID Cohort Collaborative
TL;DR: In this article , the authors used the National COVID Cohort Collaborative (N3C) to identify breakthrough infections between December 1, 2020, and May 31, 2021.
Journal ArticleDOI
SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group.
José Luis Piñana,Lucía López-Corral,Rodrigo Martino,Juan Montoro,Lourdes Vázquez,Ariadna Pérez,Gabriel Martin-Martin,Ana Facal-Malvar,Elena Ferrer,Maria-Jesús Pascual,Gabriela Sanz-Linares,Beatriz Gago,Andrés Sanchez-Salinas,Lucia Villalon,Venancio Conesa-Garcia,María Telesa Olave,Javier López-Jiménez,Sara Marcos-Corrales,Marta Garcia-Blazquez,Valentín García-Gutiérrez,Jose Angel Hernandez-Rivas,Ana Saus,I Espigado,Carmen Alonso,Rafael Hernani,Carlos Solano,Blanca Ferrer-Lores,Manuel Guerreiro,Montserrat Ruiz-García,Juan Luis Muñoz-Bellido,David Navarro,Angel Cedillo,Anna Sureda +32 more
TL;DR: In this paper, a multicenter prospective observational study which included a large cohort of allogeneic (allo-HSCT) and autologous (ASCT) hematopoietic stem cell transplant (n = 86) recipients who were monitored for antibody detection within 3 to 6 weeks after complete SARS-CoV-2 vaccination from February 1st 2021 to July 20th 2021.
References
More filters
Journal ArticleDOI
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
S. Vincent Rajkumar,Meletios A. Dimopoulos,Antonio Palumbo,Joan Bladé,Giampaolo Merlini,Maria-Victoria Mateos,Shaji Kumar,Jens Hillengass,Efstathios Kastritis,Paul G. Richardson,Ola Landgren,Bruno Paiva,Angela Dispenzieri,Brendan M. Weiss,Xavier Leleu,Sonja Zweegman,Sagar Lonial,Laura Rosiñol,Elena Zamagni,Sundar Jagannath,O. Sezer,Sigurdur Y. Kristinsson,Jo Caers,Saad Z. Usmani,Juan José Lahuerta,Hans Erik Johnsen,Meral Beksac,Michele Cavo,Hartmut Goldschmidt,Evangelos Terpos,Robert A. Kyle,Kenneth C. Anderson,Brian G.M. Durie,Jesús F. San Miguel +33 more
TL;DR: The disease definition of multiple myeloma is updated to include validated biomarkers in addition to existing requirements of attributable CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions), and specific metrics that new biomarkers should meet for inclusion in the disease definition are provided.
Journal ArticleDOI
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar,Bruno Paiva,Kenneth C. Anderson,Brian G.M. Durie,Ola Landgren,Philippe Moreau,Nikhil C. Munshi,Sagar Lonial,Joan Bladé,Maria-Victoria Mateos,Meletios A. Dimopoulos,Efstathios Kastritis,Mario Boccadoro,Mario Boccadoro,Robert Z. Orlowski,Hartmut Goldschmidt,Andrew Spencer,Jian Hou,Wee Joo Chng,Saad Z. Usmani,Elena Zamagni,Kazuyuki Shimizu,Sundar Jagannath,Hans Erik Johnsen,Evangelos Terpos,Anthony Reiman,Robert A. Kyle,Pieter Sonneveld,Paul G. Richardson,Philip L. McCarthy,Heinz Ludwig,Wenming Chen,Michele Cavo,Jean Luc Harousseau,Suzanne Lentzsch,Jens Hillengass,Antonio Palumbo,Alberto Orfao,S. Vincent Rajkumar,Jesús F. San Miguel,Hervé Avet-Loiseau +40 more
TL;DR: Several aspects of disease response assessment are clarified, along with endpoints for clinical trials, and future directions for disease response assessments are highlighted, to allow uniform reporting within and outside clinical trials.
Journal ArticleDOI
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.
Noa Dagan,Noam Barda,Noam Barda,Noam Barda,Eldad Kepten,Oren Miron,Oren Miron,Shay Perchik,Mark A. Katz,Mark A. Katz,Mark A. Katz,Miguel A. Hernán,Marc Lipsitch,Ben Y. Reis,Ran D. Balicer,Ran D. Balicer +15 more
TL;DR: This study in a nationwide mass vaccination setting suggests that the BNT162b2 mRNA vaccine is effective for a wide range of Covid-19–related outcomes, a finding consistent with that of the randomized trial.
Journal ArticleDOI
Effectiveness of convalescent plasma therapy in severe COVID-19 patients.
Kai Duan,Bende Liu,Li Cesheng,Huajun Zhang,Ting Yu,Jieming Qu,Min Zhou,Li Chen,Shengli Meng,Hu Yong,Cheng Peng,Mingchao Yuan,Jinyan Huang,Zejun Wang,Jianhong Yu,Xiaoxiao Gao,Dan Wang,Xiaoqi Yu,Li Li,Jiayou Zhang,Xiao Wu,Bei Li,Yanping Xu,Wei Chen,Peng Yan,Yeqin Hu,Lin Lianzhen,Xuefei Liu,Shihe Huang,Zhou Zhijun,Lianghao Zhang,Yue Wang,Zhang Zhi,Kun Deng,Zhiwu Xia,Gong Qin,Wei Zhang,Xiaobei Zheng,Ying Liu,Huichuan Yang,Dongbo Zhou,Ding Yu,Jifeng Hou,Zhengli Shi,Sai-Juan Chen,Zhu Chen,Xinxin Zhang,Xiaoming Yang +47 more
TL;DR: CP therapy was well tolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases and the optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials.
Journal ArticleDOI
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.
Cecilie Blimark,Erik Holmberg,Ulf-Henrik Mellqvist,Ola Landgren,Magnus Björkholm,Malin Hultcrantz,Christian Kjellander,Ingemar Turesson,Sigurdur Y. Kristinsson +8 more
TL;DR: The findings confirm that infections represent a major threat to multiple myeloma patients and the effect on infectious complications due to novel drugs introduced in the treatment of multipleMyeloma needs to be established and trials on prophylactic measures are needed.
Related Papers (5)
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.
Fulvia Pimpinelli,Francesco Marchesi,Giulia Piaggio,Diana Giannarelli,Elena Papa,Paolo Falcucci,Martina Pontone,Simona di Martino,Valentina Laquintana,Antonia La Malfa,Enea Gino Di Domenico,Ornella Di Bella,Gianluca Falzone,Fabrizio Ensoli,Branka Vujovic,Aldo Morrone,Gennaro Ciliberto,Andrea Mengarelli +17 more